Liquidia Co. (NASDAQ:LQDA) is Kynam Capital Management LP's 10th Largest Position

Kynam Capital Management LP raised its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 34.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,698,324 shares of the company's stock after buying an additional 698,324 shares during the period. Liquidia comprises approximately 3.6% of Kynam Capital Management LP's holdings, making the stock its 10th largest holding. Kynam Capital Management LP owned about 4.16% of Liquidia worth $32,461,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in shares of Liquidia during the fourth quarter worth approximately $26,000. Aigen Investment Management LP acquired a new position in shares of Liquidia in the 3rd quarter valued at $80,000. Tower Research Capital LLC TRC boosted its position in shares of Liquidia by 610.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company's stock worth $108,000 after purchasing an additional 7,731 shares during the last quarter. Corton Capital Inc. grew its stake in shares of Liquidia by 14.2% during the third quarter. Corton Capital Inc. now owns 23,440 shares of the company's stock worth $149,000 after purchasing an additional 2,921 shares during the period. Finally, Greenleaf Trust bought a new stake in Liquidia in the fourth quarter valued at about $164,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Liquidia

In other news, General Counsel Russell Schundler sold 8,653 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46. Following the completion of the sale, the general counsel now owns 488,087 shares of the company's stock, valued at $7,721,536.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Jason Adair sold 4,657 shares of the business's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $15.81, for a total value of $73,627.17. Following the sale, the insider now directly owns 108,640 shares in the company, valued at $1,717,598.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Russell Schundler sold 8,653 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $136,890.46. Following the transaction, the general counsel now owns 488,087 shares of the company's stock, valued at $7,721,536.34. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 72,712 shares of company stock valued at $1,125,576. 31.60% of the stock is currently owned by corporate insiders.

Liquidia Stock Performance

NASDAQ:LQDA traded up $0.08 on Monday, reaching $13.85. The company's stock had a trading volume of 611,467 shares, compared to its average volume of 882,042. Liquidia Co. has a 1-year low of $5.71 and a 1-year high of $16.99. The business's 50-day moving average price is $13.37 and its two-hundred day moving average price is $12.74. The firm has a market cap of $1.06 billion, a PE ratio of -8.88 and a beta of 0.25.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.22). Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. The business had revenue of $2.97 million during the quarter, compared to analyst estimates of $4.31 million. As a group, sell-side analysts expect that Liquidia Co. will post -1.26 EPS for the current year.

Analyst Ratings Changes

LQDA has been the topic of a number of recent analyst reports. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of Liquidia in a report on Monday, June 3rd. HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Liquidia in a research report on Wednesday, May 15th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).